Atherosclerosis in systemic lupus erythematosus

References

• Ardoin SP, Pisetsky DS. Developments in the scientific understanding of lupus. Arthritis Res Ther. 2008; 10:218.
   PubMed Web of Science ®Google Scholar
• Thomas GN, Tam LS, Tomlinson B, Li EK. Accelerated atherosclerosis in patients with systemic lupus erythematosus: A review of the causes and possible prevention. Hong Kong Med J. 2002; 8:26–32.
   PubMedGoogle Scholar
• Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976; 60:221–225.
   PubMed Web of Science ®Google Scholar
• Nikpour M, Urowitz MB, Gladman DD. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am. 2005; 31:329–354.
   PubMed Web of Science ®Google Scholar
• Rhew EY, Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus—role of inflammatory mechanisms. Autoimmun Rev. 2006; 5:101–105.
   PubMed Web of Science ®Google Scholar
• Mok CC. Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand J Rheumatol. 2006; 35:85–95.
   PubMed Web of Science ®Google Scholar
• Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006; 1:297–329.
   PubMed Web of Science ®Google Scholar
• Blasi C. The autoimmune origin of atherosclerosis. Atherosclerosis. 2008; 201:17–320.
   PubMed Web of Science ®Google Scholar
• Sherer Y, Shoenfeld Y. Mechanisms of disease: Atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol. 2006; 2:99–106.
   PubMedGoogle Scholar
• Nilsson J, Hansson GK. Autoimmunity in atherosclerosis: A protective response losing control?. J Intern Med. 2008; 263:464–478.
   PubMed Web of Science ®Google Scholar
• Pereira IA, Borba EF. The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly. 2008; 138:534–539.
   PubMed Web of Science ®Google Scholar
• Ferencík M, Stvrtinová V, Hulín I. Defects in regulation of local immune responses resulting in atherosclerosis. Clin Dev Immunol. 2005; 12:225–234.
   PubMedGoogle Scholar
• Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TAJr., Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol. 1997; 145:408–415.
   PubMed Web of Science ®Google Scholar
• Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol. 1999; 26:2137–2143.
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Côte R, Grover SA, Fortin PR, Clarke AE, Senécal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001; 44:2331–2337.
   PubMed Web of Science ®Google Scholar
• Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999; 42:338–346.
   PubMed Web of Science ®Google Scholar
• Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97:1837–1847.
   PubMed Web of Science ®Google Scholar
• Bruce IN. ‘Not only…but also’: Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 2005; 44:1492–1502.
   PubMed Web of Science ®Google Scholar
• Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, Stein MC. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007; 66:208–214.
   PubMed Web of Science ®Google Scholar
• Colombo BM, Cacciapaglia F, Puntoni M, Murdaca G, Rossi E, Rodriguez G, Nobili F, Pisciotta L, Bertolini S, Moccetti T, Dentali F, Steidl L, Ciprandi G, Afeltra A, Indiveri F, Puppo F. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: Role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev. 2009; 8:309–315.
   PubMed Web of Science ®Google Scholar
• Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 349:2399–2406.
   PubMed Web of Science ®Google Scholar
• Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol. 1994; 21:1264–1267.
   PubMed Web of Science ®Google Scholar
• Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. Semin Nephrol. 2003; 23:406–411.
   PubMed Web of Science ®Google Scholar
• Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993; 44:638–642.
   PubMed Web of Science ®Google Scholar
• Colombo BM, Murdaca G, Caiti M, Rodriguez G, Grassia L, Rossi E, Indiveri F, Puppo F. Intima-media thickness: A marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann N Y Acad Sci. 2007; 1108:121–126.
   PubMed Web of Science ®Google Scholar
• de Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus. 2006; 15:675–682.
   PubMed Web of Science ®Google Scholar
• Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol. 2005; 25:1776–1785.
   PubMed Web of Science ®Google Scholar
• Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, Witztum JL, Frostegård J.. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 20011887: 93–104.
   Google Scholar
• Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, Teh LS, Bernstein RM, Walker MG, Bruce IN. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): The relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford). 2007; 46:983–988.
   PubMed Web of Science ®Google Scholar
• Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 349:2399–2406.
   PubMed Web of Science ®Google Scholar
• George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, Barshack I, Kopolovic J, Shoenfeld Y. Immunolocalization of β2 glycoprotein I(apolipoprotein H) to human atherosclerotic plaques: Potential implications for lesion progression. Circulation. 1999; 99:2227.
   PubMed Web of Science ®Google Scholar
• George J, Harats D, Gilburd B, Afek A, Shaish A, Kopolovic J, Shoenfeld Y. Adoptive transfer of beta-2-glycoprotein-I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation. 2000; 102:1822.
   PubMed Web of Science ®Google Scholar
• George J, Afek A, Gilburd B, Levy Y, Blank M, Kopolovic J, Harats D, Shoenfeld Y. Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus. 1997; 6:723.
   PubMed Web of Science ®Google Scholar
• Afek A, George J, Shoenfeld Y, Gilburd B, Levy Y, Shaish A, Keren P, Janackovic Z, Goldberg I, Kopolovic J, Harat D. Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice. Pathobiology. 1999; 67:19.
   PubMed Web of Science ®Google Scholar
• George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, . Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation. 1998; 98:1108.
   PubMed Web of Science ®Google Scholar
• George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I, Kopolovic Y, Wick G, Shoenfeld Y, Harats D. Hyperimmunization of apo-E mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis. 1998; 138:147.
   PubMed Web of Science ®Google Scholar
• Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases—mechanisms and clinical findings. Clin Rev Allergy Immunol. 2009; 37:20–28.
   PubMed Web of Science ®Google Scholar
• Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, Gilburd B, Corbanese S, Patnaik M, Zampieri S, Peter JB, Favaretto E, Iaccarino L, Sherer Y, Todesco S, Pauletto P. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003; 62:1071–1077.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342:836–843.
   PubMed Web of Science ®Google Scholar